Search

Displaying results 6341 - 6350 of 10000 in total
  1. Drug

    PRGN-3006

    go.drugbank.com/drugs/DB17229
    Investigational

    PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface

    Synonyms: PRGN-3006 UltraCAR-T, Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface
  2. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). … OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors.

  3. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    The usage of the INN stem '-rasib' in the name indicates that Fulzerasib is a Ras protein inhibitor. … Fulzerasib is under investigation in clinical trial NCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-

  4. Drug

    Zanidatamab zovodotin

    go.drugbank.com/drugs/DB15472
    Experimental

    According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload." … [L8234] It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies

  5. Drug

    N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide

    go.drugbank.com/drugs/DB06940
    Experimental

    This compound belongs to the pyrrolotriazines. These are compounds containing a pyrrolotriazine moiety, which consists of a pyrrole ring fused to a triazine ring. … N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide is known to target mitogen-activated protein kinase 14.

  6. Drug

    Cirazoline

    go.drugbank.com/drugs/DB09202
    Experimental

    Cirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain.

    Categories: Adrenergic alpha-1 Receptor Agonists
  7. Drug

    EPC2407

    go.drugbank.com/drugs/DB05189
    Investigational

    These tumors include the frequently occurring cancers of the lung, gastrointestinal tract, ovaries, and breast. … It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized.

  8. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    This substance targets the protein peroxisome proliferator-activated receptor gamma. … It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.

  9. Drug

    Azemiglitazone

    go.drugbank.com/drugs/DB16028
    Investigational

    Azemiglitazone is under investigation in clinical trial NCT01280695 (A Randomized, Double-blind, Comparator- and Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability and Efficacy

  10. Drug

    Insulin efsitora alfa

    go.drugbank.com/drugs/DB19013
    Investigational

    Basal Insulin for the First Time (QWINT-1)). … Insulin efsitora alfa is under investigation in clinical trial NCT05662332 (A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting